Volume 3.07 | Feb 24

Cord Blood News 3.07, February 24, 2012
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
A Low Frequency of Pancreatic Islet Insulin-Expressing Cells Derived from Cord Blood Stem Cell Allografts in Humans
Cord blood stem cells have the capacity to differentiate into insulin-expressing cells in non-diabetic humans. It remains to be established whether these cells have the properties of beta cells. [Diabetologia]


social_default_facebook_icon.jpg Cell Therapy News is now on Facebook. Join us!

social_default_twitter_icon.jpg Follow us on Twitter!  @Cord_Blood_News

Interested in recruiting talented individuals? Post your career opportunities in Cord Blood News at no cost. Contact us at [email protected]

Human Umbilical Cord Blood Cells Aid Diabetic Wound Healing
Transplanting human umbilical cord blood-derived endothelial progenitor cells (EPCs) has been found to “significantly accelerate” wound closure in diabetic mouse models, said a team of Korean researchers. [Press release from EurekAlert! discussing online prepublication in Cell Transplantation]

Study Confirms Third Trimester Amniotic Fluid a Reliable Source of Stem Cells for Regenerative Medicine and Stem Cell Banking
In a study that was presented at the Society for Maternal-Fetal Medicine’s annual meeting in San Francisco, Biocell Center, together with a group of collaborators, confirmed that amniotic fluid collected during the third trimester of pregnancy is a reliable source of stem cells for regenerative medicine and stem cell banking. [PR Newswire]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

The Replication Rate of Human Hematopoietic Stem Cells In Vivo
Researchers’ simulations provide evidence that the number of human hematopoietic stem cells (HSCs) increases from birth until adolescence and then plateaus, and that the ratio of contributing to quiescent HSCs in man significantly differs from mouse. In addition, they suggest that human marrow failure, such as the marrow failure that occurs after umbilical cord blood transplantation and with aplastic anemia, results from insufficient numbers of early progenitor cells, and not the absence of HSCs. [Blood]

Human Cord Blood-Derived Endothelial Progenitor Cells and Their Conditioned Media Exhibit Therapeutic Equivalence for Diabetic Wound Healing
In this study, human cord blood-derived endothelial progenitor cell transplantation stimulated keratinocyte and fibroblast proliferation substantially as early as 3 days after injury, leading to significantly accelerated wound closure in streptozotocin-induced diabetic nude mice, compared to PBS control. [Cell Transplant]

Mesenchymal Stem Cells in Ex Vivo Cord Blood Expansion
Current strategies directed at improving TNC and CD34+ cell doses at transplant are discussed, with particular attention paid to the use of a mesenchymal stem cell/cord blood mononuclear cell ex vivo co-culture expansion system. [Best Pract Res Clin Haematol]

Multi-Type Branching Models to Describe Cell Differentiation Programs
The expansion of human cord blood CD34+ cells by hematopoietic growth factors was division tracked in bulk culture using carboxyfluorescein diacetate, succinimidyl ester. [J Theor Biol]

Adults Requiring Cord Blood Transplants But Have Insufficient Cell Doses from a Single Cord Blood Unit Can Receive Two Units with Successful Engraftment Kinetics Similar to Those of Children Receiving a Single Unit
Data indicate that adults without sufficient nucleated cell doses in a single cord blood unit may receive two units with similar engraftment kinetics to those of children receiving only a single unit. [Leuk Lymphoma]

Isolation and Expansion of Oligodendrocyte Progenitor Cells from Cryopreserved Human Umbilical Cord Blood
Results demonstrate that oligodendrocyte precursor cells can be derived reliably from thawed, cryopreserved human umbilical cord blood units, and support the feasibility of using these cells in human clinical trials. [Cytotherapy]

Pretransplant Serum Ferritin Is Associated with Bloodstream Infections Within 100 Days of Allogeneic Stem Cell Transplantation for Myeloid Malignancies
Peripheral blood stem cell transplantation (n = 23) showed a greater protective effect against bloodstream infections compared with bone marrow (n = 71) and cord blood (n = 20) transplantation. [Int J Hematol]

In Vitro Trans-Differentiation of Human Umbilical Cord Derived Hematopoietic Stem Cells into Hepatocyte Like Cells Using Combination of Growth Factors for Cell Based Therapy
Results show a new strategy for differentiation in a short duration, using a combination of growth factors for the differentiation of umbilical cord blood derived hematopoietic stem cells into hepatocyte like cells under certain in vitro conditions. [Cytotechnology]

T Lymphoid Differentiation Potential Measured In Vitro Is Higher in CD34+CD38-/lo Hematopoietic Stem Cells from Umbilical Cord Blood Than From Bone Marrow and Is Cell Intrinsic
Data shows that cord blood hematopoietic stem cells have higher T lymphoid differentiation potential than bone marrow hematopoietic stem cells and that this property is cell autonomous. [Haematologica]

China Cord Blood Corporation Forms Zhejiang Subsidiary 
China Cord Blood Corporation announced the formation of Zhejiang Lukou Biotechnology Co., Ltd., an indirect non-wholly owned subsidiary with the Zhejiang Provincial Blood Center, pursuant to the Company’s framework agreement announced in September 2010. [China Cord Blood Corporation Press Release]

Tissue Engineering Methods Earn Funding to Heal Little Hearts
Texas Children’s Hospital in Houston announced that a researcher in its Pediatric Cardiac Bioengineering Laboratory has earned a National Science Foundation Early Career Development (CAREER) Award for his work in studying the causes of congenital heart disease, heart defects, and the development of tissue engineering therapies using stem cells derived from human amniotic fluid. [EurekAlert!]

Stemedica Receives Approval from UCSD to Initiate Ischemic Stroke Study with Adult Allogeneic Stem Cells
Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development announced today that it has received IRB approval from the University of California, San Diego (UCSD) to initiate a Stemedica clinical study entitled, “A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke.” [Stemedica Cell Technologies, Inc. Press Release]

Fate Therapeutics Announces Emerging Data from Proof-of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation
Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase Ib clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii (Abstract Number: 198; entitled, “Ex Vivo Treatment of Hematopoietic Stem Cells with 16, 16-dimethyl Prostaglandin E2 (FT1050) Improves Engraftment and Hematopoietic Reconstitution”). [Fate Therapeutics, Inc. Press Release]

Tarix Pharmaceuticals Enrolls First Patient in Phase II Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
Tarix Pharmaceuticals announced enrollment of the first patient in a Phase II clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow. [PR Newswire]

Champlin Earns Transplant Society’s Lifetime Achievement Award
The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group’s annual meeting. The award recognizes Champlin, head of The University of Texas MD Anderson Cancer Center Department of Stem Cell Transplantation and Cellular Biology, for his career-long work developing and improving blood stem cell transplantation as cancer therapy. [The University of Texas MD Anderson Cancer Center Press Release]

Fate Therapeutics Announces Encouraging Clinical Results and Change in Management
In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase Ib trial, Fate Therapeutics announced that Paul A. Grayson, who has been president and CEO since April 2008, is leaving Fate to form a new company. [Fate Therapeutics, Inc. Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Frozen Cord Blood Proficiency Testing Program
March 2011 or September 2011
Online Program

July 11-12, 2011
London, United Kingdom

NEW Adult MSC2011: Innovations in Cell-Based Regenerative Therapies
August 22-24, 2011
Cleveland, United States

Visit our events page to see a complete list of events in the cord blood community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Cell Therapy Manufacturing Manager (Opexa Therapeutics)

Associate Scientist – Oncology (St. Jude Children’s Research Hospital)

Postdoctoral Fellow (The Henry M. Jackson Foundation)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us